跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
HERZUMA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
HERZUMA
Authorized
STANDARD
HERZUMA
Celltrion Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
c7b2b7178ee83a3b
Company
Celltrion Inc
Type
Standard
Approval Details
Approval Id
c7b2b7178ee83a3b
Drug Approval Canada Name
HERZUMA
Product Name
HERZUMA
Status
Marketed
Status Date
2024-10-03
Original Market Date
2021-02-25
Din
02506211
Drug Class
Human
Dosage Form
Powder For Solution
Route Of Administration
Intravenous
Schedule
Schedule D , Prescription
Ahfs
10:00.00
Atc Original
L01FD01 TRASTUZUMAB
Atc Name
l 01 fd 01
Aig Number
0154252002
Company Name
Celltrion Inc
Company Address
23 Academy-Ro, Yeonsu-Gu, Incheon, --, Korea, Republic Of, 22014
Company Detail Path
/organization/celltrion-inc
Company Information
Pharmaceutical Company Name
Celltrion, Inc.
Name En
Celltrion, Inc.
Name Zh
塞尔群
Country Name
South Korea
Province Name
仁川广域市
City Name
Yeonsu-gu, Incheon
Address
Yeonsu-gu, Incheon, South Korea
Website
https://www.celltrion.com
Description
South Korean biopharmaceutical company headquartered in Incheon, developing and distributing biosimilar monoclonal antibody therapies for rheumatoid arthritis, cancer, and inflammatory diseases.
Active Ingredients
TRASTUZUMAB
150 MG / VIAL
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
c7b2b7178ee83a3b
Type
Standard
Back to Health Canada Approvals